Open AccessArterial Retention of Remnant Lipoproteins Ex Vivo Is Increased in Insulin Resistance Because of Increased Arterial Biglycan and Production of Cholesterol‐Rich Atherogenic Particles That Can Be Improved by Ezetimibe in the JCR:LA‐ cp Rat
Author(s) -
Mangat Rabban,
Warnakula Samantha,
Borthwick Faye,
Hassanali Zahra,
Uwiera Richard R.E.,
Russell James C.,
Cheeseman Christopher I.,
Vine Donna F.,
Proctor Spencer D.
Publication year - 2012
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.112.003434
Subject(s) - insulin resistance , medicine , ezetimibe , endocrinology , ex vivo , metabolic syndrome , simvastatin , cholesterol , insulin , arterial stiffness , diabetes mellitus , in vivo , blood pressure , biology , microbiology and biotechnology
Background Literature supports the “response‐to‐retention” hypothesis—that during insulin resistance, impaired metabolism of remnant lipoproteins can contribute to accelerated cardiovascular disease progression. We used the JCR:LA‐ cp rat model of metabolic syndrome ( MetS ) to determine the extent of arterial accumulation of intestinal‐derived remnants ex vivo and potential mechanisms that contribute to exacerbated cholesterol deposition in insulin resistance.Methods and Results Arteries from control and MetS (insulin‐resistant) JCR:LA‐ cp rats were perfused ex vivo with Cy5‐labeled remnant lipoproteins, and their arterial retention was quantified by confocal microscopy. Arterial proteoglycans were isolated from control and MetS rats at 6, 12, and 32 weeks of age. There was a significant increase in the arterial retention of remnants and in associated cholesterol accumulation in MetS rats as compared to control rats. Mechanistic studies reveal that increased cholesterol deposition is a result of greater arterial biglycan content; longer glycosaminoglycans and increased production of cholesterol‐rich intestinal‐derived remnants, as compared to controls. Additionally, perfusion of vessels treated with ezetimibe, alone or in combination with simvastatin, with remnants isolated from the respective treatment group reduced ex vivo arterial retention of remnant‐derived cholesterol ex vivo as compared to untreated controls.Conclusions Increased progression of atherosclerotic cardiovascular disease in MetS and type 2 diabetes mellitus might be explained in part by an increase in the arterial retention of cholesterol‐rich remnants. Furthermore, ezetimibe alone or in combination treatment with simvastatin could be beneficial in ameliorating atherosclerotic cardiovascular disease in insulin resistance and MetS .